Clinical analysis on glucose metabolism in patients with primary liver carcinoma
- VernacularTitle:原发性肝癌患者糖代谢的临床分析
- Author:
Rongrong HUANG
- Publication Type:Journal Article
- Keywords:
Liver neoplasms;
Glucose metabolism disorders;
Blood glucose;
Insulin;
C-peptide
- From:
Cancer Research and Clinic
2008;20(11):752-753,756
- CountryChina
- Language:Chinese
-
Abstract:
Objective To explore the clinical feature of glucose metabolism in patients with primary liver carcinoma (PLC). Methods Levels of blood glucose ,serum insulin and serum C peptide were estimated in fasting state and 0.5,1,2,3 h respectively after an oral ingestion of glucose with a dose of 75 g in 82 cases of PLC and other 35 controls. The insulin resistant index and β cell function index for each patient were recorded and calculated. Results There was no significant difference of serum levels of fasting glucose between test group and control group. The serum glucose level after glucose intaking and the serum levels of blood serum insulin and serum C peptide after glucose intaking were significantly higher more than that of control group (P<0.001). The insulin resistant index and β cell function index were both significantly higher than that in control group (P <0.05) while the INS index were significantly lower than those in the control group (P<0.05). Conclusion Insulin resistance, hyper-insulinemia in fasting state and dysfunction in early-stage insulin secretion exist in patients with PLC when their glucose level in normal at the fasting status. It is not only easy but also hidden to occur glucose metabolism abnormality. Thus the prevention of hepatogenous diabetes should start from the state of normal glucose regulation, especially the preservation of islet β cell function.
